Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 97 patients with Actinic Keratosis (AK) on the head or face for the on-going Limtop phase II study. The aim is to evaluate the efficacy and safety of three different dose regimens of Limtop. The results are expected in the first half of 2013.
Limtop is an innovative formulation of imiquimod for the treatment of actinic keratosis, genital warts and basal cell cancer. The objective is a product with short treatment duration, improved safety profile and similar or better efficacy than that of competing preparations.
"We are very pleased that patient recruitment has been successfully completed and that the study is proceeding according to plan. Limtop may enable field treatment and reduce the risk of side effects", says Peter Wolpert, CEO and founder of Moberg Derma.
About Limtop and actinic keratosis
Limtop is based on a patent-pending formulation of imiquimod, a proven compound, which results in an optimal dose of the active substance being delivered into the skin. Preclinical results show that Limtop has a significantly better capacity than existing preparations to transport the active substance to the target tissue in the skin. Actinic keratosis is sun damage to the skin that is characterised by thickening of the horny layer of the epidermis. The condition has become more common as a result of changed lifestyle and increased exposure to strong sunlight. Actinic keratosis can develop into squamous cell carcinoma and should thus be treated. Prevalence varies, as fair-skinned individuals are affected more. In populations in the northern hemisphere, a prevalence of 11% to 25% is reported.
About this information
Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on at 8:30 am (CET) on September 6th, 2012.
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma's first product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.se
For further information, please contact:
Peter Wolpert, President and CEO
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
Magnus Persson, IR
Mobile: +46 73 355 26 01